Clinical-Stage Biotech · Texas
Phase 2 readout in 90 days. Your D&O renewal is in 60.
Clinical-stage public biotech faces securities class actions on virtually every Phase 2/3 readout. D&O renewal pricing tracks market cap, trial stage, and recent disclosure history — and the wrong transactional D&O placement at IPO/SPAC can leave gaps that surface only after a stock drop.
We work with Texas biotech companies (UT Southwestern, MD Anderson, Baylor College of Medicine, Texas Medical Center spinouts) on D&O architecture, clinical trial liability for active studies, CTA insurance schedules, and products tower scaling at Phase 3.
Problem 01 · D&O architecture
Securities exposure tracks every readout.
Clinical-stage biotech has been the highest-frequency securities-class-action sector for the last decade. Every Phase 2 and Phase 3 readout is a disclosure event; every regulatory pause is a disclosure event; every collaboration termination is a disclosure event. D&O renewal pricing tracks market cap, recent disclosures, and pipeline concentration.
The IPO/SPAC transaction adds a second D&O placement: transactional D&O for the offering itself. This is separate from the regular renewal D&O and has its own runoff/tail mechanics. Mishandling the placement during the IPO window leaves gaps that materialize only when a post-IPO stock drop triggers a class action.
Problem 02 · Clinical trial liability
CTA insurance schedules are non-trivial.
Clinical trial agreements with sites and CROs typically require sponsor-side trial liability with $5M-$10M minimums, plus additional-insured wording for the site, CRO, and investigators. Most CTA insurance schedules are dense and inconsistent across institutions; bigger academic centers (UT Southwestern, MD Anderson, Baylor) have their own institutional schedules layered on top of standard language.
The sponsor / CRO / site indemnification dance gets contentious when a subject injury claim alleges study-design or protocol-execution failure — that can land in CRO E&O instead of sponsor trial liability. Coordination language in the CTA and on the COIs determines who pays first.
Frequently asked
Common questions from CDMO and CRO buyers
What insurance does a clinical-stage biotech need?
+
D&O is the highest priority — clinical-stage public biotech faces securities class actions on every Phase 2/3 readout. Plus clinical trial liability for active trials, products liability scaling at Phase 3, cyber for IP protection, and EPLI.
Why is biotech D&O so expensive?
+
Securities class action exposure tied to clinical readouts and regulatory news. Clinical-stage biotech has been the highest-frequency D&O claim sector for the last decade. Limits scale with market cap and trial stage.
What is clinical trial liability?
+
Coverage for bodily injury claims by clinical trial subjects arising from study participation. Most CTAs require sponsor-side coverage with $5M-$10M minimums; CRO and site indemnification dance against this policy.
Does the sponsor or the CRO carry clinical trial liability?
+
Typically the sponsor carries the trial-liability policy with the CRO and sites added as additional insureds. Allocation of injury claims between trial-liability, CRO E&O, and site malpractice depends on causation language.
When should a biotech start the D&O conversation?
+
At Series A or first board formation. Pre-financing biotech can place private-company D&O affordably; waiting until IPO/SPAC creates rushed transactional D&O placement at materially worse terms.
Is products liability needed before commercial launch?
+
Limited products is appropriate during clinical trials (the trial itself is a products exposure). Full products tower is needed at Phase 3 readout / NDA filing as the company prepares for potential commercial launch.
Free coverage review